Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bay State’s FORUM Pharma Lays Off 89 After Two Failed Clinical Trials

March 25, 2016 By Mark Terry, Breaking News Staff   Waltham, Mass.-based FORUM Pharmaceuticals, in light of two Phase III trial disappointments, is laying off half its staff and restructuring the company. In September 2015, the U.S. Food and Drug Administration (FDA) advised FORUM to halt its clinical trials of encenicline for Alzheimer’s disease. […]

Read More »

Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute

A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.   The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, […]

Read More »

Genetic study tracks start of Zika’s invasion of Americas back to 2013

The Zika virus currently sweeping through the Americas looks to have hitched a ride on a plane into Brazil in 2013 and begun its invasion of the continent from there, scientists said on Thursday.   In the first genome analysis of the current Zika epidemic, which has been linked in Brazil to cases of birth […]

Read More »

Many patients with high stroke risk do not get needed blood thinners

Patients who have a heart rhythm disorder that can come with a high risk of stroke often don’t receive blood-thinning medications that can make this complication less likely, a U.S. study suggests. Researchers studied almost 430,000 people with a condition known as atrial fibrillation, an irregular rapid heartbeat that can lead to stoke, heart failure […]

Read More »

Portola’s long-acting blood thinner misses main study goal

Portola Pharmaceuticals Inc said data showed its oral anticoagulant missed the main goal of preventing blood clots in acutely ill patients in a late-stage study. The company’s shares fell 30 percent to a two-year low of $20.00 in early trading. Portola’s betrixaban, designed for the prevention of venous thromboembolism (VTE), or blood clots, was tested […]

Read More »

U.S FDA issues draft guidance for abuse-deterrent opioid generics

The U.S. Food and Drug Administration issued draft guidance on Thursday for abuse-deterrent opioid generics, including a recommendation that studies be conducted to demonstrate that generic opioids are no less abuse-deterrent than branded drugs. The FDA said it was encouraging industry efforts to develop pain medicines that are more difficult to abuse. The regulator issued […]

Read More »

China says vaccine scandal suspect was free to re-offend

The person at the center of an illegal vaccine scandal in China had been sentenced for similar crimes but was allowed to re-offend after being given a suspended sentence, the head of a food and drug watchdog told a news conference on Thursday. The case involving a nearly $90 million black market vaccine ring has […]

Read More »

Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases

TARRYTOWN, N.Y., March 24, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases. Two separate Phase 2 clinical studies are evaluating the combination therapy as a co-formulated […]

Read More »

Ex-Apple Exec Launches At-Home Blood Test Startup in San Francisco

March 24, 2016By Alex Keown, Breaking News Staff   SAN FRANCISCO – A former Apple (AAPL) executive who helped design the Apple Watch, has founded a blood-testing company that allows users to take their own blood samples and send the information to the cloud for analysis, Techcrunch reported. Bob Messerschmidt founded Cor and the […]

Read More »

Paul G. Allen Announces $100 Million to Launch the Paul G. Allen Frontiers Group

Initial commitment toward a larger 10-year plan will create group to explore and fund frontiers in bioscience   WASHINGTON, March 23, 2016 /PRNewswire-USNewswire/ — Philanthropist and entrepreneur Paul G. Allen today announced an initial commitment of $100 million to create The Paul G. Allen Frontiers Group, whose purpose will be to explore the landscape of […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom